Vitamin Shoppe campaign to fight vitamin-A deficiency blindness
NORTH BERGEN, N.J. The Vitamin Shoppe announced Wednesday it will begin accepting cash donations on behalf of Vitamin Angels in support of that agency’s campaign, Operation 20/20, as part of the vitamin retailer’s 30th anniversary celebrations.
“With our Anniversary Sale in-store, in our catalog and on the web, we know our loyal customers will join us in supporting this important initiative to end childhood blindness caused by [vitamin-A deficiency],” stated Tony Truesdale, president and chief merchandising officer of The Vitamin Shoppe.
Vitamin Angels is committed to eliminating childhood blindness caused by vitamin-A deficiency by the year 2020. Operation 20/20 is the first major step in this global campaign, which launched this year in 15 countries.
The Vitamin Shoppe is raising funds for Vitamin Angels in store at the register. Customers can donate $1 or more to the campaign and sign a Vitamin Angels paper angel to hang in the store. Any customer who donates $5 or more will receive a special Operation 20/20 wristband as a thank you. Online customers can also donate with each purchase at www.vitaminshoppe.com.
Relora survey finds 91 percent positive response
SALINAS, Calif. Next Pharmaceuticals on Tuesday released the results of an open label study on Relora. The study was conducted at The LaValle Metabolic Institute in Cincinnati, Ohio among 1,291 participants who suffered from stress, sleeplessness and/or stress-related eating.
According to the survey, 91 percent of the subjects reported Relora helped them relax, 90 percent reported Relora helped them have a restful sleep and 86 percent reported Relora helped prevent stress-related eating.
“This study demonstrates that Relora can be a successful adjunct for individuals who experience stress and anxiety, or who turn to food when dealing with tension,” stated Charles Kosmont, chief executive officer of Next Pharmaceuticals. “There are many methods to managing stress, and Dr. LaValle’s clinical study supports the fact that Relora is a natural, safe and effective approach with no toxic side effects.”
Relora consists of a patented blend of Magnolia bark extract and a proprietary blend of Phellodendron bark extract developed by Next Pharmaceuticals for the dietary supplement and functional food and beverage industries. Dr. James LaValle, author of Cracking the Metabolic Code, was the principal investigator of the study.
The subjects rated the efficacy of Relora on a 5-point scale. The product was considered effective for stress, restful sleep and stress-related eating if the subject rated the product 3 or higher. This study was developed as an open label, single center, clinical trial involving a minimum of 500 subjects with mild to moderate stress. Dr. LaValle enrolled both male and female subjects in the study as appropriate from patients at his clinic.
Matrixx announces plans to enter antacid market with Xcid
NEW YORK Matrixx revealed plans to enter the antacid market with a product called Xcid early in 2009 Wednesday, during the Roth Conference Presentation held here. According to the company, the acid neutralizing category is currently measured at around $500 million.
Xcid, featuring “from the makers of Zicam” on the packaging, will contain maximum strength quantities of calcium carbonate and magnesium hydroxide in a liquid format and will be launched with three flavors. Liquid antacids are considered highly efficacious among consumers, Carl Johnson, Matrixx president and chief executive officer, said, but there aren’t many good-flavored products currently on the market.
Matrixx will also be entering the oral care market in 2009, and will potentially target the analgesic sector for future product development.